NightHawk Biosciences, Inc. Overview
Industry: Biotechnology
Sector: Healthcare
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
NightHawk Biosciences, Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review NightHawk Biosciences, Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
NightHawk Biosciences, Inc. Competitors
NightHawk Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans